Physician profile
Gregory Proctor
NPI 1447306063
$6,599.60
in general payments reported to CMS, 2019-2025
12 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $5,826 · 2021: $71.83 · 2022: $73.55 · 2023: $113 · 2024: $342 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $5,968.85 | 2020-2024 | Farxiga, Lokelma |
| Genentech USA, INC. | $87.95 | 2022-2024 | Ocrevus, Enspryng |
| Vifor Pharma, INC. | $86.26 | 2020 | |
| Aurinia Pharma U.S., INC. | $74.05 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.38 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $65.97 | 2024-2025 | |
| Akebia Therapeutics INC | $53.85 | 2025 | Vafseo |
| Travere Therapeutics, INC. | $51.25 | 2023-2024 | |
| Lilly USA, LLC | $46.69 | 2024-2025 | Jardiance |
| Genentech, INC. | $43.42 | 2022-2023 | Ocrevus |
| Amgen INC. | $27.51 | 2025 | Krystexxa |
| Calliditas Therapeutics US INC. | $22.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.